Evaluation of oral nano-silymarin formulation effect in prevention of liver damage induced by doxorubicin-cyclophosphamide chemotherapy regimen in patients with non-metastatic breast cancer
Phase 3
Recruiting
- Conditions
- on-metastatic breast cancer.Malignant neoplasm of breast
- Registration Number
- IRCT20200408046990N13
- Lead Sponsor
- Mashhad University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- Female
- Target Recruitment
- 70
Inclusion Criteria
Age between 18-65 y
Patients with diagnosis of non-metastatic breast cancer who will be treated by doxurobicin after mastectomy
Signing the written consent
Exclusion Criteria
Viral hepatitis
History of hypersensitivity to silymarin or similar compounds
Pregnancy and lactation
Any kind of liver injury resulting in rise of liver enzymes or bilirubin to higher than upper limit normal
Renal failure
Concomitant use of heptotoxic agents or antioxidants
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method